Rutherford, NJ, Dec. 03, 2024 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a leading innovator in medical technology for diabetes management, has announced the start of patient enrollment for its groundbreaking clinical study of the continuous blood glucose monitor (CBGM). This feasibility study will evaluate the performance of Glucotrack’s novel monitoring system in patients with both type 1 and type 2 diabetes, with initial data expected within 6-8 weeks.

The CBGM stands apart from traditional continuous glucose monitors by directly measuring blood glucose levels, eliminating the lag associated with interstitial fluid measurements. This innovative device offers a long-term, implantable solution designed for up to three years of uninterrupted use without any external on-body components, making glucose monitoring more accurate, seamless, and user-friendly.

Study Details and Visionary Leadership
The short-term, in-hospital feasibility study will involve intravascular placement of the CBGM sensor for four days. Participants will undergo controlled glucose and meal challenges to evaluate the monitor's performance.

The study is being led by Dr. Alexandre Abizaid, MD, PhD, a globally renowned interventional cardiologist and Director of Interventional Cardiology at Instituto do Coração (InCor) in São Paulo, Brazil. Dr. Abizaid has extensive experience in pioneering first-in-human clinical trials and is a Visiting Professor of Medicine at Columbia University Medical Center.

“Following the success of our preclinical program, we are thrilled to advance the development of our CBGM with this clinical milestone,” said Paul V. Goode, PhD, President and CEO of Glucotrack. “This study is a significant step in demonstrating the transformative potential of our device for people with diabetes worldwide.”

A New Standard in Glucose Monitoring
The CBGM represents a leap forward in glucose management technology, offering continuous, real-time monitoring for patients managing diabetes with intensive insulin therapy. Its ability to deliver precise, blood-based readings for years without frequent replacements aims to redefine patient convenience and care standards.

About Glucotrack, Inc. Glucotrack, Inc. (Nasdaq: GCTK) is committed to revolutionizing diabetes care through the development of innovative monitoring solutions. The Company’s continuous blood glucose monitor (CBGM) is designed to provide accurate, long-term, and hassle-free glucose measurement, empowering patients to manage their condition with confidence.

For more details, visit glucotrack.com.